Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema (Review)

Sahoo, Soumendra and Abas, Adinegara BL and Nair, Sreekumaran N (2015) Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema (Review). The Cochrane Collaboration, 2015 (2). pp. 1-13.

[img] PDF
topical non steroidal-Cochrane review.pdf - Published Version
Restricted to Registered users only

Download (172kB) | Request a copy


Background:Diabetic cystoid macular oedema (CMO) is a condition which involves fluid accumulation in the inner portion of the retina. It often follows changes in retinal blood vessels which enhance the fluid to come out of vessels. Although it may be asymptomatic, symptoms are primarily painless loss of central vision, often with the complaint of seeing black spots in front of the eye. It is reported thatCMOmay resolve spontaneously, or fluctuate formonths, before causing loss of vision. If left untreated or undiagnosed, progression of CMO may lead to permanent visual loss. It has been noted that patients with diabetic retinopathy have elevated inflammatory markers, and therefore it is likely that inflammation aids in the progression of vascular disease in these patients. Several topical non-steroidal anti-inflammatory drugs (NSAIDs) such as ketorolac 0.5%, bromfenac 0.09%, and nepafenac 0.1%, have therefore also been used topically to treat chronic diabetic CMO. Hence this review was conducted to find out the effects of topical NSAIDs in diabetic CMO. Objectives: To assess the effects of topical non-steroidal anti-inflammatory drugs (NSAIDs) for diabetic cystoid macular oedema (CMO).

Item Type: Article
Subjects: Departments at MU > Statistics
Depositing User: KMC Manipal
Date Deposited: 07 Mar 2015 04:38
Last Modified: 07 Mar 2015 04:38

Actions (login required)

View Item View Item